A month has gone by since the last earnings report for Westinghouse Air Brake Technologies (WAB) . Shares have lost about 0.4% in that time frame, outperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Wabtec due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.Wabtec Q3 Earnings Beat EstimatesWest ...

It has been about a month since the last earnings report for Knight-Swift Transportation Holdings (KNX) . Shares have lost about 5.3% in that time frame, underperforming the S&P 500.But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Knight-Swift due for a breakout? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent catalysts for Knight-Swift Transportation Holdings Inc. before ...

Elastic (ESTC) came out with quarterly earnings of $0.64 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $0.59 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +10.34%. A quarter ago, it was expected that this software developer would post earnings of $0.42 per share when it actually produced earnings of $0.6, delivering a surprise of +42.86%.Over the last four quarters, the comp ...

A month has gone by since the last earnings report for Omnicom (OMC) . Shares have lost about 11.4% in that time frame, underperforming the S&P 500.But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Omnicom due for a breakout? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent catalysts for Omnicom Group Inc. before we dive into how investors and analysts have reacted as of la ...

Company Performance - VAREX IMAGING reported quarterly earnings of $0.37 per share, exceeding the Zacks Consensus Estimate of $0.18 per share, and up from $0.19 per share a year ago, representing an earnings surprise of +105.56% [1] - The company posted revenues of $228.9 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 3.83%, compared to year-ago revenues of $205.7 million [2] - Over the last four quarters, VAREX IMAGING has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - VAREX IMAGING shares have declined approximately 21.7% since the beginning of the year, while the S&P 500 has gained 13.4% [3] - The current Zacks Rank for VAREX IMAGING is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.21 on revenues of $207.65 million, and for the current fiscal year, it is $0.97 on revenues of $861.55 million [7] - The outlook for the Medical - Products industry, to which VAREX IMAGING belongs, is currently in the bottom 30% of Zacks industries, which may impact the stock's performance [8]

Company Performance - Medtronic reported quarterly earnings of $1.36 per share, exceeding the Zacks Consensus Estimate of $1.31 per share, and up from $1.26 per share a year ago, representing an earnings surprise of +3.82% [1] - The company posted revenues of $8.96 billion for the quarter ended October 2025, surpassing the Zacks Consensus Estimate by 1.11%, compared to $8.4 billion in the same quarter last year [2] - Medtronic has surpassed consensus EPS estimates in all four of the last quarters and topped consensus revenue estimates three times during the same period [2] Stock Performance - Medtronic shares have increased approximately 20.5% since the beginning of the year, outperforming the S&P 500's gain of 13.4% [3] - The current consensus EPS estimate for the upcoming quarter is $1.35 on revenues of $8.83 billion, and for the current fiscal year, it is $5.63 on revenues of $35.8 billion [7] Industry Outlook - The Medical - Products industry, to which Medtronic belongs, is currently ranked in the bottom 30% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Medtronic's stock may be influenced by the overall outlook for the industry, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

北美经理人持仓自 10 月高点回落 ——全球股市立体投资策略周报 11 月第 2 期 本报告导读： 上周全球指数小幅收涨，欧股港股成交放量，北美经理人持仓指数继续回落。资金 面上，多位美联储官员放鹰，12 月联储降息边际趋弱。基本面上，港美科技与创新 药盈利预期上修，主要市场经济景气预期不同程度回落。 投资要点： 证 券 研 究 报 告 请务必阅读正文之后的免责条款部分 策 略 研 究 海 外 策 略 | 1. | 市场表现：上周全球市场小幅收涨 3 | | --- | --- | | 2. | 交投情绪：上周欧洲/中国香港市场成交放量 4 | | 3. | 资金流动：上周美联储放鹰降息预期再降温 8 | | 4. | 基本面：上周港美科技股/创新药盈利上修 10 | | 5. | 风险提示 13 | 研 究 策略研究 /[Table_Date] 2025.11.17 2025-11-18 [Table_Summary] 市场表现：全球市场小幅收涨。股市方面，MSCI 全球+0.4%，其中 MSCI 发达市场+0.4%、MSCI 新兴市场+0.2%。债市方面，美国 10Y 利 率上行。大宗方面，银铜涨幅居前。 ...

Core Insights - Biorestorative Therapies, Inc. (BRTX) reported a quarterly loss of $0.38 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.13 per share a year ago [1] - The company posted revenues of $0.01 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 97%, and down from $0.23 million year-over-year [2] - Biorestorative Therapies shares have declined approximately 1.4% year-to-date, while the S&P 500 has gained 16.4% [3] Financial Performance - The company has surpassed consensus EPS estimates two times over the last four quarters [1] - The current consensus EPS estimate for the upcoming quarter is -$0.28 on revenues of $0.5 million, and for the current fiscal year, it is -$1.55 on revenues of $1.23 million [7] Market Outlook - The earnings outlook and estimate revisions will significantly influence the stock's price movement [4] - The Zacks Rank for Biorestorative Therapies is currently 3 (Hold), indicating expected performance in line with the market [6] - The Medical - Biomedical and Genetics industry is ranked in the top 34% of over 250 Zacks industries, suggesting a favorable industry outlook [8]

Core Insights - Armata Pharmaceuticals reported a quarterly loss of $0.42 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.15 per share a year ago [1] - The company posted revenues of $1.16 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 16.01%, and down from $2.97 million year-over-year [2] - The stock has increased approximately 264.9% since the beginning of the year, significantly outperforming the S&P 500's gain of 16.4% [3] Financial Performance - The company has surpassed consensus EPS estimates three times over the last four quarters [1] - The current consensus EPS estimate for the upcoming quarter is -$0.41 on revenues of $1.47 million, and for the current fiscal year, it is -$1.46 on revenues of $5.5 million [7] Market Outlook - The earnings outlook and management's commentary during the earnings call will be crucial for the stock's immediate price movement [3][4] - The Zacks Rank for Armata Pharmaceuticals is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry is currently in the top 34% of over 250 Zacks industries, suggesting a favorable environment for stocks within this sector [8] - Another company in the same industry, Fortress Biotech, is expected to report a quarterly loss of $0.43 per share, with revenues projected to be $23.68 million, reflecting a year-over-year increase of 61.9% [9]

Core Insights - Green Dot (GDOT) reported strong third-quarter 2025 results, with both earnings and revenues exceeding the Zacks Consensus Estimate, yet the stock declined by 4% post-earnings release on November 10 [1] Financial Performance - Quarterly earnings per share (EPS) of 6 cents, excluding 62 cents from non-recurring items, surpassed the consensus estimated loss of 11 cents and improved by 53.9% year-over-year [2] - Revenues reached $491.9 million, beating the Zacks Consensus Estimate by 1% and increasing by 20% year-over-year [2] Segment Performance - B2B Services revenues surged by 32% to $364.2 million, driven by a BaaS partner and stability across the BaaS portfolio [3] - Money Movement Services revenues declined by 6% to $29.8 million, affected by a slight dip in Money Processing, although Tax Processing saw revenue growth [3] - Consumer Services segment revenues fell by 10% to $88.3 million, primarily due to secular headwinds in the Retail channel, partially offset by the recent launch of PLS [4] Key Metrics - Gross dollar volume increased by 18% to $39.5 million, while purchase volume decreased by 5.1% to $4.74 billion [5] - Active accounts rose by 0.9% year-over-year to 3.51 million [5] - Adjusted EBITDA totaled $23.57 million, down 17% year-over-year, with the adjusted EBITDA margin decreasing by 220 basis points to 4.8% [6] Balance Sheet & Cash Flow - Green Dot ended the third quarter with $1.64 billion in unrestricted cash and cash equivalents, up from $1.59 billion at the end of Q4 2024, and had no long-term debt [7] - The company generated $201.03 million in cash from operating activities [7] Guidance - Green Dot provided 2025 guidance for total operating revenues between $2 billion and $2.1 billion, with the midpoint aligning with the Zacks Consensus Estimate [8] - Adjusted EPS guidance was raised to a range of $1.31-$1.44, above the previous range of $1.28-$1.42, with the midpoint exceeding the Zacks Consensus Estimate of $1.35 [9] - Adjusted EBITDA is expected to be between $165 million and $175 million, an increase from the previous guidance of $160 million to $170 million [9]